Anti-proliferative effects of novel T-type calcium channel blocker KCP10043F in human pancreatic cancer cells through Ca/CaMKII pathway via ER stress induction.

Pancreatic cancer is among the most lethal cancer types with a 5-year survival rate of approximately 5 %. Although a T-type calcium channel blocker, 4-(4-fluorobenzylcarbamoylmethyl)-3-(4-cyclohexylphenyl)-2-[3-(N,N-dimethylureido)-N'-methylpropylamino]-3,4-dihydroquinazoline (KCP10043F, OZ-001), previously exhibited the anti-tumor effects in lung cancer, its anti-proliferative effects and the specific molecular mechanisms in pancreatic cancer remain unclear. This study was conducted to evaluate the anti-proliferative effects of KCP10043F on human pancreatic cancer cell lines, PANC-1 and MIA PaCa-2. 1) KCP10043F suppressed cell growth and colony formation, and promoted the G1 phase cell retention by downregulating G1 phase-related proteins; 2) KCP10043F triggered apoptotic cell death via the intrinsic pathway by upregulating BH3-only Bcl-2 family proteins; 3) At the molecular level, KCP10043F inhibited the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (p70S6K) pathway and activated the c-Jun N-terminal kinase (JNK)/c-Jun pathway; 4) KCP10043F mediated the Ca/Calcium-calmodulin-dependent kinase II (CaMKII) pathway by inducing endoplasmic reticulum (ER) stress; 5) α-Tocopherol controlled KCP10043F-induced cell cycle arrest and apoptosis by attenuating ER stress. These results demonstrate the potential of KCP10043F as a therapeutic candidate for human pancreatic cancer.